ATE411038T1 - S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung - Google Patents

S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung

Info

Publication number
ATE411038T1
ATE411038T1 AT04723142T AT04723142T ATE411038T1 AT E411038 T1 ATE411038 T1 AT E411038T1 AT 04723142 T AT04723142 T AT 04723142T AT 04723142 T AT04723142 T AT 04723142T AT E411038 T1 ATE411038 T1 AT E411038T1
Authority
AT
Austria
Prior art keywords
protein
activator
cancer treatment
neutrophil cells
reduce neutropenia
Prior art date
Application number
AT04723142T
Other languages
English (en)
Inventor
Philippe Tessier
Karen Vandal
Pascal Rouleau
Carle Ryckman
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Application granted granted Critical
Publication of ATE411038T1 publication Critical patent/ATE411038T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04723142T 2003-03-28 2004-03-25 S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung ATE411038T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45802203P 2003-03-28 2003-03-28

Publications (1)

Publication Number Publication Date
ATE411038T1 true ATE411038T1 (de) 2008-10-15

Family

ID=33098257

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04723142T ATE411038T1 (de) 2003-03-28 2004-03-25 S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung

Country Status (6)

Country Link
US (1) US7632802B2 (de)
EP (1) EP1608397B1 (de)
AT (1) ATE411038T1 (de)
CA (1) CA2520515C (de)
DE (1) DE602004017148D1 (de)
WO (1) WO2004084928A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327075D1 (de) * 2002-07-05 2009-05-20 Univ Laval Der entzündungsreaktionen
WO2006005186A1 (en) * 2004-07-13 2006-01-19 UNIVERSITé LAVAL S100 protein inhibitors for treating leukemia
AU2007315073A1 (en) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceuticals that promote functional regeneration of damaged tissues
AU2009240885A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
WO2009133939A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
KR20110017371A (ko) * 2008-04-30 2011-02-21 가부시키가이샤 제노믹스 생체내 기능적 세포의 고효율 채취법
US8173598B2 (en) 2008-08-29 2012-05-08 The Board Of Trustees Of The University Of Illinois Myeloid protein activation of anti-inflammatory and anti-hypoxic pathway
KR20120135190A (ko) 2009-10-28 2012-12-12 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제
CN103687946B (zh) 2011-04-26 2017-05-03 吉诺米克斯股份有限公司 用于诱导组织再生的肽及其应用
PL2913058T3 (pl) 2012-10-25 2018-04-30 Genomix Co., Ltd. Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1
CN104955470B (zh) 2012-10-25 2017-06-16 吉诺米克斯股份有限公司 利用了hmgb1片段的针对脊髄损伤的新型治疗方法
WO2016134463A1 (en) * 2015-02-25 2016-09-01 UNIVERSITé LAVAL S1009a peptide for treating leukemias
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
JPWO2019107530A1 (ja) 2017-12-01 2020-11-26 株式会社ステムリム 炎症性腸疾患の治療薬
US12421498B2 (en) 2017-12-01 2025-09-23 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
FR2587707B1 (fr) 1985-09-23 1988-01-08 Compiegne Universite Technolog Glycopeptide et toute composition le contenant, leur procede de preparation et leurs applications anticoagulantes
EP0263072B1 (de) 1986-10-03 1994-03-23 Ciba-Geigy Ag Lymphokin-ähnliche Peptide
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
WO1992004376A1 (en) 1990-09-05 1992-03-19 The Heart Research Institute Limited Novel chemotactic factor
EP0573904B1 (de) 1992-06-08 2001-09-26 Takeda Chemical Industries, Ltd. Therapeutisches Agens für Neutropenie
AU5420796A (en) 1996-03-11 1997-10-01 Human Genome Sciences, Inc. Chemotactic cytokine ii
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
DE19811047C1 (de) 1998-03-13 1999-04-15 Fraunhofer Ges Forschung Metallhaltige Ribonukleotidpolypeptide
US6117989A (en) 1998-03-26 2000-09-12 Incyte Pharmaceuticals, Inc. Human calcium-binding proteins
EP1121454B1 (de) 1998-10-06 2007-11-14 The Trustees of Columbia University in the City of New York Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
EP1066834A3 (de) 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
DE60327075D1 (de) 2002-07-05 2009-05-20 Univ Laval Der entzündungsreaktionen
WO2006005186A1 (en) 2004-07-13 2006-01-19 UNIVERSITé LAVAL S100 protein inhibitors for treating leukemia

Also Published As

Publication number Publication date
EP1608397B1 (de) 2008-10-15
WO2004084928A1 (en) 2004-10-07
CA2520515C (en) 2012-08-28
US20060281674A1 (en) 2006-12-14
EP1608397A1 (de) 2005-12-28
DE602004017148D1 (de) 2008-11-27
US7632802B2 (en) 2009-12-15
CA2520515A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
ATE411038T1 (de) S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
van Putten et al. Macrophage phenotypes in the collagen-induced foreign body reaction in rats
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
ATE381336T1 (de) Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
WO2003066072A3 (en) Cell therapy using immunoregulatory t-cells
van Leuven et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis
Sonouchi et al. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
DE602004019965D1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
ATE540973T1 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
EA201190080A1 (ru) Стабильные формы гранулоцитарных колоний рекомбинантного человеческого альбумина, стимулирующие фактор гибридного белка
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EP1603391A4 (de) Verfahren zur verwendung von zusammensetzungen, umfassend hitzeschockproteine oder alpha-2-macroglobulin bei der behandlung von krebs und infektionskrankheiten
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
Mocellin et al. Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment
EP2083018A3 (de) Zusammensetzungen und Verfahren mit Bezug zu STOP-1
EA200600936A1 (ru) Способы регуляции фактора некроза опухоли альфа
CN105506155A (zh) 检测长链非编码rna loc284454表达量的试剂的应用
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
Arai et al. A solid tumor of donor cell-origin after allogeneic peripheral blood stem cell transplantation
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
RU2003100172A (ru) Способ терапии инфаркта миокарда

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties